The Lancet Respiratory Medicine

ISSN: 2213-2600

Journal Home

Journal Guideline

The Lancet Respiratory Medicine Q1 Unclaimed

Elsevier Ltd. United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Lancet Respiratory Medicine launched in March 2013 as the fourth Lancet specialty journal following in the footsteps of The Lancet Oncology, The Lancet Neurology, and The Lancet Infectious Diseases. The journal offers the same unique fast track experience offered by its sister journals for all authors of research papers that are selected for peer review, where articles can be published online within 8 weeks of submission. The Lancet Respiratory Medicine is indexed in PubMed, and has been approved for indexing and abstracting in SciSearch®, Journal Citation Reports, and Current Contents® by Thomson Reuters. It has an SJR impact factor of 11,204.

The Lancet Respiratory Medicine focuses its scope in these topics and keywords: pulmonary, chronic, randomised, obstructive, disease, fibrosis, idiopathic, cromoglicate, air, indian, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Price

4598 €

Inmediate OA

0 €

Embargoed OA

0 €

Non OA

Metrics

The Lancet Respiratory Medicine

11,204

SJR Impact factor

159

H Index

274

Total Docs (Last Year)

939

Total Docs (3 years)

4770

Total Refs

13753

Total Cites (3 years)

402

Citable Docs (3 years)

16.69

Cites/Doc (2 years)

17.41

Ref/Doc

Comments

No comments ... Be the first to comment!

Aims and Scope


pulmonary, chronic, randomised, obstructive, disease, fibrosis, idiopathic, cromoglicate, air, indian, indacaterol, assessment, health, guidancethe, girl, formulation, asthmachildhood, doubleblind, diagnosisoncedaily, degradation, biomarkers, cough, copdlandmark, controlled, consultations, collagen, cleaning, classification, change, bedaquiline, call, burden,



Best articles by citations

New antibiotic discovered for Gram-positive bacteria

View more

Mastering breathlessness in patients with advanced respiratory disease

View more

Space travel: medicine in extremes

View more

Statistical methods for evaluating delirium in the ICU

View more

Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data

View more

Would pan-tuberculosis treatment regimens be cost-effective?

View more

Improving outcomes in prolonged mechanical ventilation: a road map

View more

Transcriptional phenotyping of fibrotic lung disease: a new gold standard?

View more

South Africa confronts colliding respiratory epidemics

View more

Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis

View more

Respiratory infections in patients undergoing mechanical ventilation

View more

Pollution control up in the air

View more
SHOW MORE ARTICLES

Expression of concern

View more

The nasal microbiota in infants with cystic fibrosis in the first year of life: a prospective cohort study

View more

ARDS: promising insights for a challenging syndrome

View more

Adenotonsillectomy improves asthma outcomes in children

View more

Efficacy and safety of landiolol, an ultra-short-acting beta1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial

View more

Selman Abraham Waksman

View more

Why use the home sleep test?

View more

Retraction and republication - Effect of early versus late or no tracheostomy on mortality of critically ill patients receiving mechanical ventilation: a systematic review and meta-analysis

View more

Emerging respiratory infections: influenza, MERS-CoV, and extensively drug-resistant tuberculosis

View more

Syria: the ongoing crisis

View more

Ageing society and allergies challenge German health care

View more

2015 American Thoracic Society International Conference

View more

FAQS